Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modification of sample size in group sequential clinical trials.

L Cui1, H M Hung, S J Wang

  • 1Division of Biometrics I, OB/CDER, Food and Drug Administration, Rockville, Maryland 20852, USA. cuil@cder.fda.gov

Biometrics
|April 21, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Species of sandflies and prevalence of <i>Leishmania</i> infections in sandflies in selected areas of northern and northwestern China].

Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control·2026
Same author

Exhaled breath condensate metabolomics reveals conserved networks and bidirectional crosstalk in asthma and CRSwNP.

Rhinology·2026
Same author

[Gross classification of gallbladder cancer with primary lesion limited to the gallbladder wall and its correlation with prognosis and precancerous lesions].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences·2026
Same author

[Effect of CD4<sup>+</sup>T cell-specific methyltransferase-like 3 gene knockout on calcipotriol-induced atopic dermatitis in mice].

Zhonghua yi xue za zhi·2025
Same author

[Global epidemiology and control strategies of Chikungunya virus: a review].

Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control·2025
Same author

[A case of bilateral chylous aqueous humor].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2025
Same journal

Acknowledgment of Referees 2025.

Biometrics·2026
Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
Same journal

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same journal

Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

Biometrics·2026
See all related articles

Sample size reestimation in group sequential trials can inflate type I errors. A new procedure preserves error rates while increasing statistical power, offering a more reliable approach for clinical trial design.

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Statistical Methods

Background:

  • Group sequential clinical trials allow for interim analyses.
  • Sample size reestimation in these trials presents challenges, particularly regarding type I error inflation.
  • Existing methods for sample size adjustment can compromise trial integrity.

Purpose of the Study:

  • To develop a novel group sequential test procedure.
  • To address the issue of type I error inflation during sample size reestimation.
  • To enhance statistical power in clinical trials without compromising accuracy.

Main Methods:

  • Simulation studies were conducted to evaluate the impact of sample size adjustments.
  • A new group sequential test procedure was developed by modifying weights in the traditional repeated significance two-sample mean test.

Related Experiment Videos

  • The proposed method focuses on preserving type I error probability.

    • Main Results:

    • Simulation results indicated that increasing sample size based on interim estimates can significantly inflate type I error rates.
    • The new group sequential test procedure successfully preserved the type I error probability at the target level.
    • The developed procedure demonstrated a substantial gain in statistical power with increased sample size.

    Conclusions:

    • The novel group sequential test procedure offers a robust solution for sample size reestimation in clinical trials.
    • This method effectively controls type I error while improving the trial's ability to detect treatment effects.
    • The procedure provides a more reliable and powerful framework for adaptive clinical trial designs.